Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint

As Roche keeps building its catalog of positive Tecentriq results, its Phase III IMpower132 study meets PFS endpoint in NSCLC, with OS data coming later.